BioSpace News Archive

Rhythm Pharmaceuticals today announced that Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to IMCIVREE

Fusion Pharmaceuticals Inc. today announced the appointment of Eric S. Hoffman , Ph.D. as senior vice president, business development.

Pear Therapeutics, Inc. today announced that Julia Strandberg, Chief Commercial Officer, will participate in a panel discussion at the fourth annual DTx East 2021 conference being held September 28-30 in Boston and virtually.

Gossamer Bio, Inc. today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha (“efti” or “IMP321”) in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021.

On the morning of September 12, 2021, a complex endovascular intervention was performed at Changhai Hospital of China Naval Medical University by Professor Qing-Sheng Lu’s team using ALLVAS™, China’s first endovascular intervention robot developed by Shanghai Aopeng Medical Technology Co.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter of its 2022 fiscal year, which ended August 31

CuriRx, Inc., a leading contract research (CRO) and product development organization, announced today the launch of their new CuriLytics™ platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that the China National Intellectual Property Administration has granted a new patent covering DUET-02, one of three key CpG-STAT3 inhibitors comprising the Duet Platform.

HALO Diagnostics (HALO Dx) now offers men with suspected metastatic and recurrent prostate cancer another groundbreaking advanced imaging option.